The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1114
Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
Another long-acting Methylphenidate (Metadate CD)
Methylphenidate is now available in a new extended-release formulation (Metadate CD - Celltech) for treatment of attention deficit/hyperactivity disorder (ADHD). The new product, which is a Schedule II controlled substance, is being advertised...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1114
 


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.